New Report “Market Access Brazil: Unlocking Pharma Potential” Published by MarketPublishers.com
01 Sep 2011 • by Natalie Aster
LONDON – Following the election of President Dilma Rousseff this year, Brazil has shown readiness for encouraging long-term foreign investment in the pharmaceutical industry. Though three critical path priorities to ensure investment flows into the country have already been set, there remain serious concerns, with price setting, the ‘big stick’ of the compulsory licenses, burdensome tax laws, slow product approvals and linguistic barriers being the key issues. Competition from government-favoured generics and a high volume in illegally-traded drugs, which represent 25% of all pharmaceuticals sold, are also among complicating matters.
The new report “Market Access Brazil: Unlocking Pharma Potential” elaborated by FirstWord provides a clear insight into, and offers a compelling overview of Brazil’s pharmaceutical industry, examining health care responsibilities and the role of the National Health Surveillance Agency (ANVISA) to consumer trends, the latest patent protection issues, the role of generics and ongoing battle over intellectual property. The study is supplemented with interviews with experts, financial comparatives and updates from multinationals in the region.
Report Details:
Title: Market Access Brazil: Unlocking Pharma Potential
Published: July, 2011
Pages: 38
Price: US$ 795.00
Report Contents:
Executive Summary
Introduction
The Brazilian pharmaceutical market
Healthcare provision
Health sector responsibilities
ANVISA
Principal pharmaceutical patent legislation
Patent protection
Pharmaceutical patent applications (Jan 2001-Jan 2011)
Accessing the Brazilian pharmaceutical market
Trends in the Brazilian pharmaceutical market
Prescription Data for Brazil, 2009/10
Pharmaceuticals in Brazil, User Profile
Pharmaceutical Production in Brazil by Type of Capital, 2010
Intellectual Property
Generics
Estimated Market Shares of the Top 10 Pharma Companies in Brazil, June 2011
Licensing agreements
Measures to ensure the legality of medicines in Brazil
Interview with Marin Osorio, Senior Secretary, Ministry of Health
Price control
New reimbursement legislation
Multiple trade marks
The ’Pipeline Mechanism’
Investing within a protectionist environment
Establishing a presence in Brazil
The Brazilian market in comparative perspective
Pharma sector competitive infrastructure index in Latin American markets (June 2010)
Latin American pharmaceutical market sizes: Estimates and forecasts, 2009-14
Latin American agreements influencing Brazil’s pharma industry
Company Updates
The Brazilian pharmaceutical market: Some recent deals
Ache
Amgen
Bristol-Myers Squibb
Eurofarma
Novartis
Roche
To order the report or ask for free sample pages, please contact [email protected]
CONTACTS
The Market Publishers, Ltd.
Tanya Rezler
Tel: +44 208 144 6009
Fax: +44 207 900 3970
Analytics & News
